ZAPALJENJE PLUĆA IZAZVANO MIKOPLAZMOM PNEUMONIJE

Autori

  • Andreja Prijić Kliničko-bolnički centar “Dr Dragiša Mišović - Dedinje” Bolnica za dečije plućne bolesti i tuberkulozu, Beograd, Srbija
  • Olivera Ostojić Specijalna bolnica „Sokobanja“, Sokobanja, Srbij
  • Jasmina Jocić Stojanović Kliničko-bolnički centar “Dr Dragiša Mišović - Dedinje” Bolnica za dečije plućne bolesti i tuberkulozu, Beograd, Srbija
  • Milka Micić Stanojević Specijalna bolnica „Sokobanja“, Sokobanja, Srbija
  • Vesna žVeković Specijalna bolnica „Sokobanja“, Sokobanja, Srbija
  • Sergej Prijić Institut za zdravstvenu zaštitu majke i deteta Srbije, Beograd, Medicinski fakultet Univerziteta u Beogradu, Beograd, Srbija
  • Zorica Živković Kliničko-bolnički centar “Dr Dragiša Mišović - Dedinje” Bolnica za dečije plućne bolesti i tuberkulozu, Beograd, Univerzitet Privredna akademija u Novom Sadu, Farmaceutski fakultet, Novi Sad, Srbija

DOI:

https://doi.org/10.46793/PP151024013P

Ključne reči:

Mikoplazma pneumonije, zapaljenje pluća, makrolidni antibiotici

Apstrakt

Uvod. Zapaljenje pluća izazvano mikoplazmom pneumonije predstavlja atipičnu manifestaciju ovog oboljenja u pedijatrijskoj populaciji.

Prikaz bolesnika. U našem radu prikazujemo bolesnika uzrasta 9,5 godina obolelog od pneumonije, kod kojeg je dokazana infekcija mikoplazmom pneumonije sa komplikovanim kliničkim tokom. Takođe, registrovan je slab odgovor na primenjenu antimikrobnu terapiju čiju osnovu su činili makrolidni antibiotici. Zbog kliničke sumnje na multiplu etiologiju oboljenja i sa ciljem pravovremene prevencije potencijalnih kompikacija primenjena je kombinovana antibiotska terapija, nakon koje se registruje regresija oboljenja i normalizacija kliničkog stanja.

Zaključak.Infekcije izazvane mikoplazmom pneumonije u pedijatrijskoj populaciji su obično povezane sa blagim kliničkim tokom. Međutim, navedeni mikroorganizam ne retko uzrokuje atipično zapaljenje pluća, koje može da ima komplikovan klinički tok sa nezadovoljavajućim odgovorom na primenjenu terapiju, što zahteva dijagnostičku reevaluaciju oboljenja sa korekcijom terapijskog pristupa.

Reference

Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008 Nov;32(6):956-73.

Lee KY. Paediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther. 2008 Aug;6(4):509-21.

Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest. 2007 Dec;132(6):1962-6.

Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2012 Feb;55(2):42-7.

Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Paediatrics. 2004 Apr;113(4):701-7.

Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995 Jun;14(6):471-7.

Gendrel D, Raymond J, Moulin F, Iniguez JL, Ravilly S, Habib F, et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis. 1997 May;16(5):388-91.

Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998 Oct;17(10):865-71.

Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J. 1998 Nov;17(11):986-91.

Principi N, Esposito S, Blasi F, Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001 May 1;32(9):1281-9.

Tsolia MN, Psarras S, Bossios A, Audi H, Paldanius M, Gourgiotis D, et al. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis. 2004 Sep 1;39(5):681-6.

Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr. 2010;10:48.

Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011 Oct;66 Suppl 2:ii1-23.

Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in paediatric patients. J Infect Chemother. 2009 Dec;15(6):380-3.

Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006 Feb;50(2):709-12.

Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011 Jun;17(6):1079-82.

Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother. 2011 Feb;17(1):114-8.

Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006 Mar;41(3):263-8.

##submission.downloads##

Objavljeno

12/30/2016

Broj časopisa

Prev Ped 2015: 1(1)

Sekcija

Prikazi slučaja